ClinicalTrials.gg
CompletedNCT04440592Updated Dec 30, 2025Results posted

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

A Phase 2 interventional study of MT-7117 and Placebo in Diffuse Cutaneous Systemic Sclerosis, sponsored by Tanabe Pharma America, Inc.. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Enrollment
37th of 120
76 · median 29
Started
2021
with 9 others
Phase 2
41 of 153
8 open now
Registered
101st of 153
by date

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 37th largest by enrollment of the 120 interventional ones that give a count, is one of 10 that started in 2021, is one of 41 in phase 2, and was the 101st registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52

03

Conditions studied

  • Diffuse Cutaneous Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Additional screening criteria check may apply for qualification.

Inclusion criteria

Inclusion Criteria:

  • Subjects who meet all the following criteria will be considered eligible to participate in the study:

    1. Must provide signed and dated form (ICF) to participate in the study. Subjects must be able to (in the judgment of the Investigator) understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and procedures including study visits.
    2. Male or female age ≥ 18 years at screening with documented diagnosis of systemic sclerosis (SSc), as defined using the 2013 ACR/European League Against Rheumatism (EULAR) criteria.
    3. Has diffuse cutaneous form of SSc according to Leroy and Medsger's criteria.
    4. Disease duration ≤ 5 years from the first non-Raynaud's phenomenon manifestation.
    5. Has an mRSS of 15 to 45 units at screening and have clinical skin involvement proximal and distal to the elbows, knees, or both or any truncal involvement, with or without face involvement.
    6. If disease duration is > 24 months defined as time from the first non Raynaud phenomenon manifestation, subject must fulfill at least 1 of the criteria listed below that are indicatives of active disease at screening:

      1. A documentation of new skin involvement that occurred within the past 9 months, or
      2. Increase in mRSS ≥ 3 units within the past 9 months, or
      3. Presence of TFRs or,
      4. C- reactive protein (CRP) ≥ 6 mg/L, or
      5. Erythrocyte sedimentation rate ≥ 28 mm/hr, or
      6. count ≥ 330 x 10\^9/L (330,000/microliter).

      NOTE: Investigator should exclude all other acute intercurrent illness if subjects fulfilling laboratory criteria (d, e, f) only.

    7. Willing to follow restrictions regarding concomitant medications that are described.
    8. Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug.
    9. Female subjects of and male subjects with partner of child-bearing potential currently using/willing to use 2 effective methods of including barrier method as described.

Exclusion criteria

Exclusion Criteria:

- Subjects will be excluded from the study if any of the following criteria apply:

  1. Has a history or presence of rheumatic diseases other than dcSSc unless the dominant features of the disease are dcSSc, as determined by the Investigator.
  2. Has a pulmonary disease with FVC ≤ 50% of predicted at time of screening.
  3. Has a diagnosis of resting pulmonary hypertension (if exceeding estimated right ventricular systolic pressure of > 40 mmHg estimated by transthoracic echocardiography [unless the right heart catheterization is normal within the last 6 months] or mean pulmonary artery pressure > 30 mmHg as measured by right heart catheterization) and requires treatment with more than one oral medication.
  4. Has a cardiac abnormality such as left ventricular failure with \< 45%, significant arrhythmia, congestive heart failure ( Class II-IV), unstable angina, uncontrolled hypertension, or symptomatic pericardial effusion at screening.
  5. Has a history of myocardial infarction in the last 26 weeks prior to screening.
  6. Has a history of renal crisis within the past 52 weeks prior to screening.
  7. Has a documented history of chronic kidney disease (stage 4-5, an estimated [eGFR] \< 30 mL/min at screening).
  8. Presence or history of hepatobiliary disease at screening, determined as clinically significant by the Investigator after the discussion with the Sponsor Medical Monitor.
  9. (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 2.0 × (ULN), or total > 1.5 × ULN at screening.
  10. Has a history or presence of clinically significant disease not related to SSc [neurologic, renal, endocrinal, gastrointestinal cardiovascular, hepatic, dermatologic, hematological, musculoskeletal, genitourinary, thromboembolic, advanced arteriosclerosis, hyperthyroidism, moderate to severe hypertension, immunologic disease, pulmonary (e.g., uncontrolled asthma, emphysema, ) or any other disorder] as determined by the Investigator at screening. Conditions deemed not-clinically significant according to the Investigator's discretion are acceptable.
  11. Has a history or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subject.
  12. Has any clinically significant disease or laboratory abnormality judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subject at screening. Laboratory abnormalities include but not limited to any of the followings: \< 9 g/dL; WBC \< 3,000/mm3 (\< 3 x 10\^9/L); \< 100,000/mm3 (\<100 x 10\^9/L).
  13. Has a history of positive surface antigen, antibody, except for documented cure for the hepatitis B virus (HBV), defined as sustained, undetectable HBsAg and HBV DNA in serum and adequately treated hepatitis C virus (HCV) with documentation of sustained virologic response defined as undetectable HCV RNA at least 12 weeks after the end of treatment.
  14. Has a history of positive (HIV)
  15. Has a history of melanoma, familial melanoma (defined as having 2 or more first-degree relatives, such as parent, sibling, and/or child), or presence of melanoma and/or lesions suspicious for melanoma at screening.
  16. Has a presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi (Melanocytic Lesions) will be evaluated. If the suspicious lesion or nevi (Melanocytic Lesions) cannot be resolved through or excision, the subject will be excluded from the study.
  17. Has history of any other (ies) in the last 5 years with the exception of cervical carcinoma in situ.
  18. Has a history or planning to receive cell-depleting therapy or bone marrow transplantation during study treatment period.
  19. Has a history of ultraviolet (UV) phototherapy within 6 weeks prior to screening or planning to receive UV phototherapy during study treatment period.
  20. Treatment of SSc disease with

    1. Cyclophosphamide, rituximab, or cyclosporine received within 26 weeks prior to screening.
    2. Small molecules such as JAK inhibitors (e.g., tofacitinib) received within 12 weeks prior to screening.
    3. Pirfenidone received within 12 weeks prior to screening.
    4. Infliximab, certolizumab, golimumab, adalimumab, abatacept, tocilizumab within 10 weeks prior to screening.
    5. Etanercept within 4 weeks prior to screening.
    6. Oral, intravenous, or intramuscular (prednisone > 10 mg/day or equivalent) received within 30 days prior to screening
    7. Nintedanib within 12 weeks prior to screening.
    8. More than 1 of the therapy listed below as concomitant therapy with study drug, has changed one of the medication below within 12 weeks prior to screening, or not on a stable dose of the same medication for at least 12 weeks prior to screening.

      • i. Mycophenolate (up to 3 g/day), or
      • ii. Mycophenolic acid (up to 2.14 g/day), or
      • iii. Methotrexate (up to 25 mg/Week), or
      • iv. Leflunomide (up to 20 mg/day), or
      • v. Azathioprine (up to 3 mg/kg/day).
  21. Treatment with afamelanotide or other MC1R agonist within 12 weeks before screening (Visit 1).
  22. Treatment with any drugs or supplements which, in the opinion of the Investigator, may interfere with the objectives of the study or safety of the subject.
  23. Has previously exposed to MT 7117 (this does not include placebo treated subjects).
  24. Has previously treated with any agent within 12 weeks prior to screening OR 5 half-lives of the investigational product (whichever is longer).
  25. Female subjects who are pregnant, lactating, or intending to become pregnant during the study.
  26. Has a positive autoantibody status of anti-centromere antibody.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    MT-7117

    Oral tablet of MT-7117 once a day.

    Drug: MT-7117

  • Placebo comparator
    Placebo

    Oral tablet of placebo once a day.

    Drug: Placebo

Interventions

  • MT-7117

    Also known as: Dersimelagon

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The ACR CRISS Composite Score (0-1) at Week 52

    The comparison between MT-7117 treatment group and placebo group will be performed. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.

    Time frame: Week 52

Secondary outcomes

  1. Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52

    To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI). The Health Assessment Questionnaire Disability Index (HAQ-DI) is a self-administered instrument consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.

    Time frame: 52 weeks

  2. Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52

    To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC)

    Time frame: 52 weeks

  3. Change in Patient Global Assessment From Baseline up to Week 52

    To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Patient Global Assessment

    Time frame: 52 weeks

  4. Change in Physician Global Assessment From Baseline up to Week 52

    To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Physician Global Assessment. The Physician Global Assessment is used to assess the physician's rating of overall health of the subject. Physicians rate the perceived health of the subject on an 11-point scale from 0 (excellent) to 10 (extremely poor).

    Time frame: 52 weeks

  5. Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52

    To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS). mRSS evaluates a subject's skin thickness which will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.

    Time frame: 52 weeks

  6. ACR CRISS Score up to Week 39

    To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.

    Time frame: 39 weeks

  7. ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52

    To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score. Subjects with CRISS score is \>=0.60 are considered improved, while subjects with CRISS score \< 0.60 are considered not improved.

    Time frame: 52 weeks

07

Results

Posted Nov 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneMT-7117Placebo
Started3838
Completed2836
Not completed102
Withdrew: Adverse event80
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject11
Withdrew: Other therapy needed01

Outcome measures

PrimaryThe ACR CRISS Composite Score (0-1) at Week 52

The comparison between MT-7117 treatment group and placebo group will be performed. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.

Time frame:
Week 52
Reported as:
Median · scores on ascale
The ACR CRISS Composite Score (0-1) at Week 52
scores on ascaleMT-7117Placebo
The ACR CRISS Composite Score (0-1) at Week 520.8537 (0.000 to 1.000)0.8502 (0.000 to 1.000)
SecondaryChange in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52

To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI). The Health Assessment Questionnaire Disability Index (HAQ-DI) is a self-administered instrument consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.

Time frame:
52 weeks
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52
score on a scaleMT-7117Placebo
Change from baseline (BL) at Week 16-0.1439 ± 0.3803-0.0395 ± 0.3900
Change from BL at Week 26-0.0847 ± 0.3360-0.0691 ± 0.4481
Change from BL at Week 39-0.0927 ± 0.3178-0.0439 ± 0.5147
Change from BL at Week 52-0.1111 ± 0.4265-0.0208 ± 0.5102
SecondaryChange in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52

To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC)

Time frame:
52 weeks
Reported as:
Mean · %pFVC
Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52
%pFVCMT-7117Placebo
Change from BL at Week 160.754 ± 4.938-1.058 ± 5.749
Change from BL at Week 260.904 ± 5.669-0.691 ± 5.847
Change from BL at Week 39-1.201 ± 6.293-1.457 ± 5.600
Change from BL at Week 520.048 ± 6.917-2.906 ± 5.101
SecondaryChange in Patient Global Assessment From Baseline up to Week 52

To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Patient Global Assessment

Time frame:
52 weeks
Reported as:
Mean · score on a scale
Change in Patient Global Assessment From Baseline up to Week 52
score on a scaleMT-7117Placebo
Change from BL at Week 16-0.8 ± 1.8-0.3 ± 1.9
Change from BL at Week 260.0 ± 2.5-0.4 ± 2.6
Change from BL at Week 39-0.7 ± 2.2-0.5 ± 2.3
Change from BL at Week 52-0.5 ± 2.3-0.3 ± 2.5
SecondaryChange in Physician Global Assessment From Baseline up to Week 52

To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Physician Global Assessment. The Physician Global Assessment is used to assess the physician's rating of overall health of the subject. Physicians rate the perceived health of the subject on an 11-point scale from 0 (excellent) to 10 (extremely poor).

Time frame:
52 weeks
Reported as:
Mean · score on a scale
Change in Physician Global Assessment From Baseline up to Week 52
score on a scaleMT-7117Placebo
Change from BL at Week 16-1.6 ± 1.9-1.7 ± 1.8
Change from BL at Week 26-1.6 ± 2.1-1.7 ± 2.1
Change from BL at Week 39-2.1 ± 2.5-2.2 ± 2.3
Change from BL at Week 52-2.0 ± 2.9-1.7 ± 2.2
SecondaryChange in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52

To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS). mRSS evaluates a subject's skin thickness which will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.

Time frame:
52 weeks
Reported as:
Mean · score on a scale
Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52
score on a scaleMT-7117Placebo
Change from BL at Week 16-3.2 ± 4.7-3.6 ± 3.9
Change from BL at Week 26-4.9 ± 5.5-5.3 ± 6.9
Change from BL at Week 39-6.4 ± 7.0-6.2 ± 7.5
Change from BL at Week 52-6.6 ± 8.2-6.5 ± 7.9
SecondaryACR CRISS Score up to Week 39

To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.

Time frame:
39 weeks
Reported as:
Median · scores on ascale
ACR CRISS Score up to Week 39
scores on ascaleMT-7117Placebo
Week 160.0349 (0.000 to 1.000)0.1236 (0.000 to 1.000)
Week 260.2626 (0.000 to 1.000)0.6232 (0.000 to 1.000)
Week 390.3890 (0.000 to 1.000)0.5289 (0.000 to 1.000)
SecondaryACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52

To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score. Subjects with CRISS score is \>=0.60 are considered improved, while subjects with CRISS score \< 0.60 are considered not improved.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52
ParticipantsMT-7117Placebo
Week 16108
Week 261018
Week 391115
Week 521418

Adverse events

Collected over 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-71170/38 (0%)4/38 (10.5%)35/38 (92.1%)
Placebo0/38 (0%)2/38 (5.3%)28/38 (73.7%)
Most frequent serious events
Most frequent serious events
EventMT-7117Placebo
PneumoniaInfections and infestations1/380/38
Alanine aminotransferase increasedInvestigations1/380/38
Aspartate aminotransferase increasedInvestigations1/380/38
Systemic sclerodermaMusculoskeletal and connective tissue disorders1/380/38
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/380/38
Uterine polypReproductive system and breast disorders0/381/38
Organising pneumoniaRespiratory, thoracic and mediastinal disorders0/381/38
Skin ulcerSkin and subcutaneous tissue disorders1/380/38
Most frequent other events
Showing 10 of 31
Most frequent other events
EventMT-7117Placebo
Skin hyperpigmentationSkin and subcutaneous tissue disorders16/381/38
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/382/38
DiarrhoeaGastrointestinal disorders10/385/38
Skin discolourationSkin and subcutaneous tissue disorders8/380/38
NauseaGastrointestinal disorders7/382/38
VomitingGastrointestinal disorders6/382/38
COVID-19Infections and infestations4/385/38
NasopharyngitisInfections and infestations3/385/38
FatigueGeneral disorders4/383/38
Accidental overdoseInjury, poisoning and procedural complications0/384/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)MT-7117PlaceboTotal
Mean49.2 ± 12.554.2 ± 12.451.7 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)MT-7117PlaceboTotal
Female263056
Male12820
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MT-7117PlaceboTotal
Hispanic or Latino7714
Non-hispanic or Latino312960
Other022
08

Study locations

34 sites
  • Arizona Arthritis
    Glendale, Arizona 85306, United States
  • Pacific Arthritis Care Center
    Los Angeles, California 90045, United States
  • The Board of Trustees of the Leland Stanford Junior University
    Redwood City, California 94063, United States
  • Yale School of Medicine - The Anlyan Center (TAC) for Medical Research & Education
    New Haven, Connecticut 06519, United States
  • GNP Research
    Hollywood, Florida 33024, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Johns Hopkins University
    Baltimore, Maryland 21218, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109-5422, United States
  • Shelby Research, LLC
    Memphis, Tennessee 38119, United States
  • The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • UZ Leuven
    Leuven, Vlaam Gewest 3000, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman
    Liège, 4000, Belgium
  • Mount Sinai Hospital, The Rebecca Macdonald Centre For Arthritis And Autoimmune Disease
    Toronto, Ontario M5T 3L9, Canada
  • University Hospital Of Tuebingen
    Tübingen, Baden-Wuettemberg 72076, Germany
  • CIRI, Centrum fur innovative Diagnostik und Therapie Rheumatologie und Immunologie (GmbH) Am Klinikum der Johann Wolfgang Goethe-Universitat
    Frankfurt am Main, Hesse 60590, Germany
  • Internistisches Zentrum des Universitaetsklinikums Erlangen
    Erlangen, 91054, Germany
  • University of Ferrara Azienda Ospedaliero-Universitaria Sant' Anna
    Cona, Ferrera 44124, Italy
  • Universita degli Studi di Milano - Azienda Ospedaliera Istituto Ortopedico Gaetano Pini
    Milan, Lombardy 20122, Italy
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska
    Elblag, 82-300, Poland
  • Malopolskie Centrum Kliniczne
    Krakow, 30-149, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Medyczne Centrum Hetmanska
    Poznan, 60-218, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Institut d'Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Taulí
    Sabadell, Barcelona 08208, Spain
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29009, Spain
  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • The Royal Free Hospital - Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Ogasawara A, Ide R, Inoue S, Tsuda M, Teng R. Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon. Pharmacol Res Perspect. 2025 Feb;13(1):e70069. doi: 10.1002/prp2.70069. PubMed 39887900 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2024, 35 months.

Results were first posted in Nov 2025, 1 year 9 months after primary completion. A results delay was requested in Jan 2025.

Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 108. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2020
First posted
Jun 19, 2020
StartActual
Feb 5, 2021
Primary completionActual
Jan 17, 2024
CompletionActual
Feb 14, 2024
Results delay requested
Jan 10, 2025
Results first posted
Nov 3, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04440592
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Feb 5, 2021
Primary completion
Jan 17, 2024
Completion
Feb 14, 2024
Results posted
Nov 3, 2025
Last update
Dec 30, 2025

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion